Senling Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Senling Feng has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Chunsong Cheng
Lushan Botanical Garden, Chinese Academy of Sciences, Jiujiang 332900, China
1 shared publication - Jiancong Wu
Faculty of Chinese Medicine and State Key Laboratory of Mechanism and Quality of Chinese, Macau University of Science and Technology, Macau 999078, China
1 shared publication - Jie Li
Faculty of Chinese Medicine and State Key Laboratory of Mechanism and Quality of Chinese Medicine, Macau University of Science and Technology, Macau, 999078, China
1 shared publication - Qibiao Wu
Faculty of Chinese Medicine, Macau University of Science and Technology, Macao, China
1 shared publication - Wei Mo
Faculty of Chinese Medicine and State Key Laboratory of Mechanism and Quality of Chinese, Macau University of Science and Technology, Macau 999078, China
1 shared publication - Xiaoming Chen
Department of Endocrinology, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China
1 shared publication
Latest Publications
- Open Access
- 6 November 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (11) , 927
Research Progress on the Biological Activities and Clinical Applications of Pseudoprotodioscin
Background: Pseudoprotodioscin (PPD) is a prominent active steroidal saponin isolated from plants of the genus Dioscorea. Investigations have shown that PPD exhibits considerable biological activity and has great clinical potential. Methods: Dioscorea plants and pseudoprotodioscin were used as search terms for study retrieval. Studies involving PPD were collected from a wide range of databases, including China National Knowledge Infrastructure, PubMed, Web of Science, and Elsevier, as well as relevant scientific websites. Results: PPD possesses multiple bioactive properties, such as anticancer, anti-inflammatory, hepatoprotective, and cardioprotective effects. Pharmacokinetic studies in rats indicated that PPD undergoes rapid excretion and has low bioavailability (5.7%), which need to develop a more effective drug delivery system to modify, such as lipid-based nanoparticles. Additionally, Chinese patent medicines containing PPD have shown promising clinical applications in related diseases. Conclusions: This review highlights the therapeutic potential of PPD and its related Chinese patent medicines, providing a foundation for future research and clinical development. Further studies are required to optimize the pharmacokinetic profile of PPD and explore its full pharmacological potential and underlying mechanisms.
- 6 November 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (11) , 927
Open AccessResearch Progress on the Biological Activities and Clinical Applications of Pseudoprotodioscin
Background: Pseudoprotodioscin (PPD) is a prominent active steroidal saponin isolated from plants of the genus Dioscorea. Investigations have shown that PPD exhibits considerable biological activity and has great clinical potential. Methods: Dioscorea plants and pseudoprotodioscin were used as search terms for study retrieval. Studies involving PPD were collected from a wide range of databases, including China National Knowledge Infrastructure, PubMed, Web of Science, and Elsevier, as well as relevant scientific websites. Results: PPD possesses multiple bioactive properties, such as anticancer, anti-inflammatory, hepatoprotective, and cardioprotective effects. Pharmacokinetic studies in rats indicated that PPD undergoes rapid excretion and has low bioavailability (5.7%), which need to develop a more effective drug delivery system to modify, such as lipid-based nanoparticles. Additionally, Chinese patent medicines containing PPD have shown promising clinical applications in related diseases. Conclusions: This review highlights the therapeutic potential of PPD and its related Chinese patent medicines, providing a foundation for future research and clinical development. Further studies are required to optimize the pharmacokinetic profile of PPD and explore its full pharmacological potential and underlying mechanisms.